Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 645

The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.

Attention‐Deficit‐Hyperactivity Disorder: An Update

Dopheide, Julie A., Pliszka, Steven R.·2009·Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Abstract

Attention‐deficit‐hyperactivity disorder (ADHD) is a common neuropsychiatric disorder that impairs social, academic, and occupational functioning in children, adolescents, and adults. In patients with ADHD, neurobiologic research has shown a lack of connectivity in key brain regions, inhibitory control deficits, delayed brain maturation, and noradrenergic and dopaminergic dysfunction in multiple brain regions. The prevalence of this disorder in the United States is 6–9% in youth (i.e., children and adolescents) and 3–5% in adults. Prevalence rates for youth are similar worldwide. Children with ADHD are at greater risk than children without ADHD for substance abuse and delinquency whether or not they receive drug therapy; however, early treatment with psychoeducation as well as drug therapy and/or behavioral intervention may decrease negative outcomes of ADHD, including the rate of conduct disorder and adult antisocial personality disorder. Drug therapy is effective for all age groups, even preschoolers, and for late‐onset ADHD in adults. Stimulants, such as methylphenidate and amphetamine, are the most effective therapy and have a good safety profile; although recent concerns of sudden unexplained death, psychiatric adverse effects, and growth effects have prompted the introduction of other therapies. Atomoxetine, a nonstimulant, has no abuse potential, causes less insomnia than stimulants, and poses minimal risk of growth effects. Other drug options include clonidine and guanfacine, but both can cause bradycardia and sedation. Polyunsaturated fatty acids (fish oil), acetyl‐l‐carnitine, and iron supplements (for youth with low ferritin levels) show promise in improving ADHD symptoms. As long‐term studies show that at least 50% of youth are nonadherent with their drug therapy as prescribed over a 1‐year period, longacting formulations (administered once/day) may improve adherence. Comorbid conditions are common in patients with ADHD, but this patient population can be treated effectively with individualized treatment regimens of stimulants, atomoxetine, or bupropion, along with close monitoring.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1592/phco.29.6.656

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 134 references

Research works printed but not linked: 2

  1. Jensen P.S., 2004, NIMH multimodal treatment study of ADHD follow‐up: 24‐month outcomes of treatment strategies for ADHD, Pediatrics, 114, 754
  2. 10.1161/CIRCULATIONAHA.107.189473 · DOI · Paper page

Cited by

See all 645

Metadata

Authors
Dopheide, J. A., & Pliszka, S. R.
Venue
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Publisher
Wiley
Published
2009-06
Volume
29
Issue
6
Pages
656-679
ISSN
  • 0277-0008 (ISSN-L)
  • 1875-9114
OpenAlex
W1977761077
Cited by
645
References
134
FWCI
55.19
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Attention‐Deficit‐Hyperactivity Disorder: An Update. https://app.cochat.ai/papers/10.1592/phco.29.6.656
The paper
Dopheide, J. A., & Pliszka, S. R. (2009). Attention‐Deficit‐Hyperactivity Disorder: An Update. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.29.6.656

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.